About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
Twitter List
Legislative Tracking Tools
Daily Archives: September 23, 2009
How To Register for FDA’s Part 15 Meeting on Social Media
According to FDA: 1) Go to www.regulations.gov 2) Search for docket FDA-2009-N-0441-0001 (or type "Internet promotion" in the search box) 3) The search results will display the FR notice and under the "Actions" column on the far right there are … Continue reading
Posted in Miscellaney
2 Comments
FDLI Conference Part 4 – The Final Day
With the best of intentions, I set out to live blog from the FDLI Conference. While Day 1 did not afford me an electrical outlet or a dynamic laptop battery, the second day I successfully planted myself next to an … Continue reading
Posted in FDA Policy
2 Comments